drugset / Trial / NCT00999414

UARK 2009-32 Compassionate Use Study of Carfilzomib

NCT00999414

Expanded access No longer available University of Arkansas Onyx Therapeutics, Inc. · collab

Summary

This is a compassionate use, open-label, IND study for the purpose of providing carfilzomib to patients with relapsed or resistant refractory multiple myeloma.

Timeline

Start
2009-11
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Carfilzomib Other / unclassified 27 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 36 mg/m2 Intravenous

Indications